Malignant neoplasms and venous thromboembolism

doi:10.3969/j.issn.1004-583X.2016.04.007

Abstract

Abstract: Venous thromboembolism (VTE) is a major complication of malignant neoplasms,and is one of the leading causes of death in patients with malignant neoplasms. The incidence of VTE in this particular population is widely increasing.Several risk factors for developing venous thrombosis usually coexist in malignant neoplasms patients. Effective prophylaxis and treatment of VTE would reduce morbidity and mortality,and improve quality of life. This review will focus on the pathophysiology,risk factors,and as well as discuss the prevention and management regimens of VTE in malignant neoplasms.

Key words: venous thromboembolism, neoplasms, complications, prevention, therapy

CLC Number:

R619.2

Jiang Mingming, Yuan Yadong. Malignant neoplasms and venous thromboembolism[J]. Clinical Focus, 2016, 31(4): 373-377.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.04.007

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I4/373

References

[1] Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]. Arch Intern Med,2006,166(4):458-464.
[2] Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment[J]. Cancer Investig,2009,27(1):105-115.
[3] Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis[J]. PLoS Med,2012,9(7):e1001275.
[4] Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy[J]. Clin Cancer Res,2009,15(22):6830-6840.
[5] Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor[J]. Lancet,1995,346(8981):1004-1005.
[6] Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited[J]. Blood Rev,2001,15(2):61-67.
[7] Longenecker GL,Beyem BJ,Bowen RJ,et al.Human rhabdosarcoma cell-induced aggregation of blood platelets[J].Cancer Res,2005,49(1);16-19.
[8] Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials [J]. Lancet,2010,376(9754):1741-1750.
[9] Carrier M, Le Gal G, Wells PS, et al. Systematic review: the trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?[J].Ann Intern Med,2008,149(5):323-333.
[10] Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular devel-opment[J]. Arterioscler Thromb Vasc Biol,2004,24(6):1015-1022.
[11] Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer[J]. Am J Med, 2006,119(1):60-68.
[12] 王蓓,曹素艳,王雁.老年肿瘤患者合并肺栓塞的临床调查[J].中国老年医学杂志,2007,26(6):426-428.
[13] Zhang Y, Yang Y, Chen W, Guo L, et al. Prevalence and associations of venous thromboembolism in patients with newly diagnosed lung cancer[J]. Chest, 2014,146(3):650-658.
[14] Khorana AA, Francis CW, Culakova E,et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients[J]. Cancer,2007,110 (10):2339-2346.
[15] Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma[J]. J Thromb Haemost,2004,2(10):1760-1765.
[16] Alexander M, Kirsa S, Wolfe R. Thromboembolism in lung cancer-an area of urgent unmet need[J]. Lung Cancer,2014,84(3):275-280.
[17] Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous hromboembolism: results from the Vienna Cancer and Thrombosis Study[J]. Haematologica,2013,98(8):1309-1314.
[18] Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study[J].J Thromb Haemost,2006,4(3):529-535.
[19] 片玲玲,王旭,牛超,等.恶性肿瘤合并静脉血栓栓塞107例临床分析[J].临床荟萃,2012,27(14):1226-1229.
[20] 李金玲,代俊利,黄艳,等.肺癌合并静脉血栓栓塞症的危险因素研究[J].医学与哲学,2015,36(4B):26-28.
[21] Chew HK, Davies AM, Wun T,et al. The incidence of venous thromboembolism among patients with primary lung cancer[J]. J Thromb Haemost,2008,6(4):601-608.
[22] Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]. Arch Intern Med,2006,166(4):458-464.
[23] White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures[J]. Thromb Haemost,2003,90(3):446-455.
[24] Lyman GH,Khorana AA,Falanga A,et al.American Society of Clinical Oncology Guideline: recommendations for venous thmmboembolism prophylaxis and treatment in patients with cancer[J].J Clin Oncol,2007,25(34):5490-5505.
[25] 张国忠,杨琛腾,左敏,等.静脉血栓栓塞症相关危险因素研究进展[J].河北医科大学学报,2015,26(7):858-862.
[26] Holbrook A, Schulman S, Witt DM, et al. Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl):e152S-e184S.
[27] Khorana AA, Kuderer NM, Culakova E, et al.Development and validation of a predictive model for chemotherapy-associated thrombosis[J].Blood,2008,111(10):4902-4907.
[28] Pabinger I,Thaler J,Ay C.Biomarkers for prediction of venous thromboembolism in cancer[J].Blood,2013,122(12):2011-2018.
[29] Sohne M, Kruip MJHA, Nijkeuter M, et al.Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism[J]. J Thromb Haemost,2006,4(5):1042-1046.
[30] Konstantinides SV,Torbicki A,Agnelli G,et al.2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,2014,35(43):3033-69,3069a-3069k.
[31] Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. J Thromb Haemost, 2013,11(1):56-70.
[32] Rondina MT, Uyen T, Pendleton Robert C, et al. A pilot study utilizing whole body 18-FDG PET CT as a comprehensive screening strategy for occult malignancy in patient with unprovoked venous thromboembolism[J]. Thromb Res,2012,129(1):22-27.
[33] Kayatani H, Matsuo K, Ueda Y, et al. Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy[J]. Intern Med,2012,51(19):2767-2770.
[34] Kyoungkyg Bae, Woon-Jung Kwon, Seong Hoon Choi. A case report:cavitary infarction caused by pulmonary tumor thrombotic microangiopathy in a patient with pancreatic intraductal papillary mucinous neoplasm[J].Korean J Radiol, 2015,16(4):936-941.
[35] Barni S, Labianca R, Agnelli G,et al.Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study[J]. J Transl Med,2011,20(9):179.
[36] Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review[J]. GynecolOncol,2007,105(3):813-819.
[37] Hull RD,Pineo GF,Brant RF,et al. Long-term low-molecular-weight heparin versus usual care in proximal vein thrombosis patients with cancer[J]. Am J Med,2006,119(12):1062-1072.